Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study
- 1 January 1999
- journal article
- clinical trial
- Published by Springer Nature in Investigational New Drugs
- Vol. 17 (1) , 89-95
- https://doi.org/10.1023/a:1006271618635
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Computerized Quantitation of Synergism and Antagonism of Taxol, Topotecan, and Cisplatin Against Human Teratocarcinoma Cell Growth: a Rational Approach to Clinical Protocol DesignJNCI Journal of the National Cancer Institute, 1994
- Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.Journal of Clinical Oncology, 1994
- Growth of sensitive and drug-resistant human myeloid leukemia cells in SCID mice.1994
- Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia.1993
- A bayesian strategy for screening cancer treatments prior to phase ii clinical evaluationStatistics in Medicine, 1993
- Effects of CPT‐11 in combination with other anti‐cancer agents in cultureInternational Journal of Cancer, 1992
- Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line.1991
- DIFFERENTIAL REQUIREMENT OF DNA-REPLICATION FOR THE CYTO-TOXICITY OF DNA TOPOISOMERASE-I AND TOPOISOMERASE-II INHIBITORS IN CHINESE-HAMSTER DC3F CELLS1989
- ARREST OF REPLICATION FORKS BY DRUG-STABILIZED TOPOISOMERASE I-DNA CLEAVABLE COMPLEXES AS A MECHANISM OF CELL KILLING BY CAMPTOTHECIN1989
- On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complexBiochemistry, 1989